Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression

Biological Psychiatry

Volumn 74, Issue 10, 2013, Pages 734-741

  Huang, Chih Chia ^a,b   Wei, I Hua ^b   Huang, Chieh Liang ^a   Chen, Kuang Ti ^b   Tsai, Mang Hung ^b   Tsai, Priscilla ^d   Tun, Rene ^d   Huang, Kuo Hao ^a,b   Chang, Yue Cune ^c   Lane, Hsien Yuan ^a,b   Tsai, Guochuan Emil ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAMKANG UNIVERSITY   (Taiwan)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Anxiety; elevated plus maze; forced swimming test; glutamate; N methyl D aspartate; sarcosine

Indexed keywords

CITALOPRAM; DESIPRAMINE; GLYCINE TRANSPORTER 1; SARCOSINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; FATIGUE; FEMALE; FORCED SWIMMING TEST; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR DEPRESSION; MALE; MAZE TEST; MIGRAINE; NAUSEA; NONHUMAN; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REMISSION; SEDATION; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; TACHYCARDIA; TENSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANXIETY; ELEVATED PLUS MAZE; FORCED SWIMMING TEST; GLUTAMATE; N-METHYL-D-ASPARTATE; SARCOSINE;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; RATS; RATS, WISTAR; SARCOSINE;

EID: 84886644646     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.02.020     Document Type: Article

References (51)

1. R.C. Kessler, K.A. McGonagle, S. Zhao, C.B. Nelson, M. Hughes, and S. Eshleman Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey Arch Gen Psychiatry 51 1994 8 19
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Association Washington, DC 1994
3. M.B. Keller, P.W. Lavori, T.I. Muller, J. Endicott, W. Coryell, and R.M. Hirschfeld Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects Arch Gen Psychiatry 49 1992 809 816
4. G.E. Crane Cycloserine as an antidepressant agent Am J Psychiatry 115 1959 1025 1026
5. I.G. Epstein, K.G.S. Nair, and L.G. Boy The treatment of human tuberculosis with cycloserine Prog Rep Dis Chest 29 1955 241 257
6. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36
7. G.E. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, and N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 55 2004 452 456
8. H.Y. Lane, Y.C. Chang, Y.C. Liu, C.C. Chiu, and G.E. Tsai Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study Arch Gen Psychiatry 62 2005 1196 1204
9. G.E. Tsai, and P.Y. Lin Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis Curr Pharm Des 16 2010 522 537
10. R. Depoortère, G. Dargazanli, G. Estenne-Bouhtou, A. Coste, C. Lanneau, and C. Desvignes Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 30 2005 1963 1985
11. O. Malkesman, D.R. Austin, T. Tragon, G. Wang, G. Rompala, and A.B. Hamidi Acute d-serine treatment produces antidepressant-like effects in rodents Int J Neuropsychopharmacol 12 2011 1 14
12. M. Beneyto, and J.H. Meador-Woodruff Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder Neuropsychopharmacology 33 2008 2175 2186
13. G. Nowak, G.A. Ordway, and I.A. Paul Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims Brain Res 675 1995 157 164
14. A. Kugaya, and G. Sanacora Beyond monoamines: glutamatergic function in mood disorders CNS Spectr 10 2005 808 819
15. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
16. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, and S. Khalife A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression Arch Gen Psychiatry 67 2010 793 802
17. American Psychiatric Association Structured Clinical Interview for DSM-IV 1994 American Psychiatric Press Washington, DC
18. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
19. H.Y. Lane, C.L. Huang, P.L. Wu, Y.C. Liu, Y.C. Chang, and P.Y. Lin Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia Biol Psychiatry 60 2006 645 649
20. H.Y. Lane, Y.C. Liu, C.L. Huang, Y.C. Chang, C.H. Liau, and C.H. Perng Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study Biol Psychiatry 63 2008 9 12
21. H.Y. Lane, C.H. Lin, Y.J. Huang, C.H. Liao, Y.C. Chang, and G.E. Tsai A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia Int J Neuropsychopharmacol 13 2010 451 460
22. E. Frank, R.F. Prien, R.B. Jarrett, M.B. Keller, D.J. Kupfer, and P.W. Lavori Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence Arch Gen Psychiatry 48 1991 851 855
23. W. Guy ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, MD
24. M.H. Trivedi, D.W. Morris, B.D. Grannemann, and S. Mahadi Symptom clusters as predictors of late response to antidepressant treatment J Clin Psychiatry 66 2005 1064 1070
25. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, and K. Elgen The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand 334 Suppl 1987 1 100
26. R.J. Rodgers, and N. Johnson Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety Pharmacol Biochem Behav 52 1995 297 303
27. J.R. Calabrese, T. Suppes, C.L. Bowden, G.S. Sachs, A.C. Swann, and S.L. McElroy A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 61 2000 841 850
28. F.B. Hu, J. Goldberg, D. Hedeker, B.R. Flay, and M.A. Pentz Comparison of population-averaged and subject-specific approaches for analyzing repeated binary outcomes Am J Epidemiol 147 1998 694 703
29. R.D. Porsolt, G. Anton, N. Blavet, and M. Jalfre Behavioural despair in rats: A new model sensitive to antidepressant treatments Eur J Pharmacol 47 1978 379 391
30. L. Chen, M. Muhlhauser, and C.R. Yang Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo J Neurophysiol 89 2003 691 703
31. G.B. Varty, C.A. Morgan, M.E. Cohen-Williams, V.L. Coffin, and G.J. Carey The gerbil elevated plus-maze, I: Behavioral characterization and pharmacological validation Neuropsychopharmacology 27 2002 357 370
32. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: Recent developments and future needs Trends Pharmacol Sci 23 2002 238 245
33. S. Maeng, C.A. Zarate Jr, J. Du, R.J. Schloesser, J. McCammon, and G. Chen Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 2008 349 352
34. C. Zarate Jr, R. Machado-Vieira, I. Henter, L. Ibrahim, N. Diazgranados, and G. Salvadore Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18 2010 293 303
35. S.M. Breedlove, N.V. Watson, and M.R. Rosenzweig Learning and memory In: Biological Psychology: An Introduction to Behavioral, Cognitive, and Clinical Neuroscience 6th ed. 2010 Sinauer Associates, Inc. Sunderland, MA 536-539
36. G.E. Hardingham, and H. Bading Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders Nat Rev Neurosci 11 2010 682 696
37. A. Sreekumar, L.M. Poisson, T.M. Rajendiran, A.P. Khan, Q. Cao, and J. Yu Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 457 2009 910 914
38. F. Jentzmik, C. Stephan, K. Miller, M. Schrader, A. Erbersdobler, and G. Kristiansen Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours Eur Urol 58 2010 12 18
39. E.A. Struys, A.C. Heijboer, J. van Moorselaar, C. Jakobs, and M.A. Blankenstein Serum sarcosine is not a marker for prostate cancer Ann Clin Biochem 47 Pt 3 2010 282
40. M. Pavlou, and E.P. Diamandis The search for new prostate cancer biomarkers continues Clin Chem 55 2009 1277 1279
41. G. Tsai, P. Yang, L. Chung, N. Lange, and J.T. Coyle D-serine added to antipsychotic for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089
42. G. Tsai, P. Yang, Y. Chang, and M. Chong D-alanine added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 59 2006 230 234
43. B.R. Rutherford, J.R. Sneed, and S.P. Roose Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis J Affect Disord 140 2012 57 65
44. S.M. Stahl Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline Biol Psychiatry 48 2000 894 901
45. A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, and R. Churchill Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis Lancet 373 2009 746 758
46. B.N. Yu, G.L. Chen, N. He, D.S. Ouyang, X.P. Chen, and Z.Q. Liu Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19 Drug Metab Dispos 31 2003 1255 1259
47. J.W. Hsu, T.P. Su, C.Y. Huang, Y.S. Chen, and Y.H. Chou Fast onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: A 6-week double-blind, randomized comparative study J Clin Psychopharmacol 31 2010 577 581
48. C.H. Lin, S.H. Lin, and F.L. Jang Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: A randomized, double-blind, controlled study J Clin Psychopharmacol 31 2011 563 568
49. A.A. Hohmann Gender bias in psychotropic drug prescribing in primary care Med Care 27 1989 478 490
50. G. Salvadore, B.R. Cornwell, V. Colon-Rosario, R. Coppola, C. Grillon, and C.A. Zarate Jr Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine Biol Psychiatry 65 2009 289 295
51. B. Kundermann, J. Hemmeter-Spernal, P. Strate, S. Gebhardt, M.T. Huber, and J.C. Krieg Pain sensitivity in major depression and its relationship to central serotoninergic function as reflected by the neuroendocrine response to clomipramine J Psychiatr Res 43 2009 1253 1261